Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin plus Tucidinostat for HER2-negative Advanced Breast Cancer
ChiCTR2200058723Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin and tucidinostat in breast cancer, sponsored by Henan Cancer Hospital. Primary endpoints: Recommended phase 2 dose (RP2D) and Progression-free survival (PFS). Planned start Apr 2022; status: not yet recruiting.
02
Drugs
eribulintucidinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200058723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058723.